BioNxt Solutions Inc Stock Price, News & Analysis

BioNxt Solutions (OTCQB:BNXTF) has announced the continuation of Terry Lynch as capital markets advisor and the retention of two new investor relations professionals. Terry Lynch, CEO of Power Metallic Mines, brings significant early-stage capital markets experience in resource and bioscience sectors.

The company has hired Rob Grace and Blaine Ruzcki for investor relations services for a six-month period. Grace will receive CAD 20,000 monthly while Ruzcki will receive CAD 40,000 monthly, plus GST. Each professional will also receive 1,000,000 stock options exercisable at $0.88 for 18 months, vesting over 12 months according to CSE's mandatory schedule.

BioNxt Solutions (OTCQB:BNXTF) has successfully completed proof-of-concept trials for its Semaglutide oral dissolvable film (ODF) program at its German subsidiary, Vektor Pharma TF GmbH. The company developed promising prototypes showing rapid disintegration, homogeneous film quality, good manufacturability, and favorable mechanical properties.

The company plans to file a patent application in the coming months and will proceed with formulation optimization, stability studies, and scale-up work. A preclinical animal study is planned for early 2026, followed by a pilot clinical study targeted for the second half of 2026.

This development aims to provide an alternative to existing Semaglutide treatments (Ozempic® and Rybelsus®), which generated over $29.3 billion in sales in 2024. The ODF format is designed to offer a non-invasive, accessible alternative to current injectable and tablet options.

BioNxt Solutions (OTCQB:BNXTF) has announced a debt settlement agreement with an arm's length creditor to resolve an outstanding debt of $225,010. The settlement involves issuing 112,505 common shares at a deemed price of CAD$1.00 per share and making a cash payment of $112,505.

The issued shares will be subject to a mandatory four-month and one-day hold period, in compliance with Canadian Securities Exchange (CSE) policies and Canadian securities laws. The completion of this debt settlement is contingent upon receiving necessary regulatory approvals, including CSE approval.

BioNxt Solutions (OTCQB:BNXTF) has successfully completed its up-listing from OTC to the OTCQB market, with trading commencing on September 5, 2025. The company will maintain its listing on the Canadian Securities Exchange under the symbol "BNXT".

CEO Hugh Rogers highlighted the company's progress, noting three proprietary sublingual drug development programs in Europe and an upcoming chemotherapy drug delivery deal in North America. The OTCQB up-listing is expected to increase visibility and accessibility to U.S. investors, with the company committing to regular financial disclosures and compliance with OTCQB standards.

BioNxt Solutions (OTC:BNXTF) has announced the receipt of Semaglutide API, enabling the start of laboratory-scale development for their oral dissolvable film (ODF) delivery system. The company will conduct development activities at their German partner Gen-Plus GmbH in Munich, focusing on optimizing drug incorporation, testing peptide stability, and developing analytical methods.

The development program aims to create an alternative delivery method for Semaglutide, a GLP-1 receptor agonist currently marketed as Ozempic® and Rybelsus®, which generated over $29.3 billion in sales in 2024. BioNxt plans to file a provisional patent in Q3 2025 and is positioning this as the first in a series of GLP-1-based therapies using their ODF platform.

BioNxt Solutions (OTC:BNXTF) has announced two strategic investor relations engagements to enhance its market presence in German-speaking regions. The company has engaged Apaton Finance GmbH for a three-month period from August 25 to November 28, 2025, at a fee of €56,000 per month for investor relations and brand visibility services.

Additionally, BioNxt has contracted Cayo Ventures GmbH for services from August 25 to December 31, 2025, with a fee structure of up to €30,000 per week, adjustable based on trading days and cash management decisions. Both engagements are terminable at the company's discretion and involve no equity compensation.

BioNxt Solutions (OTC:BNXTF) has achieved two significant intellectual property milestones for its neurological autoimmune drug delivery platform. The company has initiated fast-track patent examination for BNT23001, its novel sublingual thin-film cladribine formulation for multiple sclerosis, through the USPTO's Track One Program, potentially securing patent protection within 12 months.

Additionally, BioNxt received acceptance of core claims for a broad international patent extending into the 2040s, protecting its sublingual thin-film delivery technology across multiple diseases and applications. The company's lead product targets a combined addressable market of $42-46 billion by 2032 for MS and generalized myasthenia gravis (GMG). BioNxt aims to demonstrate superior bioavailability compared to Merck's MAVENCLAD®, which generated over $1 billion in sales in 2023.

BioNxt Solutions (OTC:BNXTF) has successfully closed the final tranche of its oversubscribed convertible debenture unit private placement, raising $241,200 in gross proceeds. Combined with the previous tranche, the total offering reached $1,250,400.

The debenture units, priced at $0.60 each, consist of 8.0% unsecured convertible debentures and one common share purchase warrant. The warrants are exercisable at $0.75 per share for two years. The debentures feature an 8.0% annual interest rate and are convertible into common shares at $0.60 per share. The company plans to use the proceeds for product development, commercialization, IP filings, and working capital.

BioNxt Solutions (OTC:BNXTF) has received positive communications from both the European Patent Office (EPO) and Eurasian Patent Organization (EAPO) regarding its patent applications for a proprietary sublingual Cladribine thin-film formulation. The patents cover the use of chemotherapy drugs in oral dissolvable delivery systems for treating autoimmune neurological diseases.

The company's technology focuses on treating relapsing-remitting multiple sclerosis (RRMS) through a sublingual administration method designed to optimize drug absorption and improve patient compliance. The patent protection extends to the film composition, administration methods, dosage, and manufacturing processes.

BioNxt has also filed patent applications in other major markets including the United States, Canada, Japan, Australia, and New Zealand. The company is preparing for GMP manufacturing and a human bioequivalence clinical study in Europe to support regulatory filings and commercialization.